Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2018-04-25 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
独立董事关于第九届董事会第十六次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from the independent directors of a company regarding several matters discussed at the 16th meeting of the 9th board of directors. It includes opinions on the 2017 profit distribution plan, reappointment of the audit firm for 2018, asset impairment provisions, accounting policy changes, a subsidiary's equity transfer, and the 2018 guarantee limit. The document references compliance with laws, regulations, and company articles, and it is intended to be submitted to the 2017 annual shareholders' meeting for approval. The content is focused on governance and board-level decisions rather than financial results or audit reports themselves. It is not a full annual report, audit report, or earnings release. It is also not a simple announcement or certification but a formal independent opinion related to board meeting matters. This fits best under Board/Management Information (MANG), which covers announcements of changes or opinions from the board or senior management regarding company matters.
2018-04-25 Chinese
第九届监事会第八次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It discusses the approval of several reports including the 2017 Annual Report, 2017 Supervisory Board Work Report, 2017 Financial Final Report, 2018 Financial Budget Report, 2017 Profit Distribution Plan, 2017 Internal Control Evaluation Report, asset impairment provision, accounting policy changes, and the 2018 Q1 Report. The document does not contain the full reports themselves but rather the resolutions approving these reports and mentions that the full reports are available on the Shanghai Stock Exchange website. The document length is short (2122 characters) and it serves as an official announcement of the Supervisory Board's meeting resolutions rather than the reports themselves. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a formal announcement of supervisory board decisions and approvals related to various reports, not the reports themselves.
2018-04-25 Chinese
关于计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's decision to make asset impairment provisions for the fiscal year ending December 31, 2017. It details the amounts of impairment for bad debts, goodwill, and other assets, and explains the impact on the company's profit. The document includes statements from the board of directors, independent directors, the supervisory board, and the audit committee supporting the impairment decision. The document is relatively short (1700 characters) and is an announcement of a specific accounting action rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). It is also not a certification or regulatory compliance filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-04-25 Chinese
审计报告
Regulatory Filings
2018-04-25 Chinese
关于中源协和细胞基因工程股份有限公司非经营性资金占用及其他关联资金往来情况汇总表的专项审核报告
Regulatory Filings
2018-04-25 Chinese
关于续聘会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of an accounting firm (瑞华会计师事务所) as the auditor for the company's 2018 fiscal year. It includes details about the audit fees and an independent director's opinion on the auditor's qualifications. The document states that this matter will be submitted to the 2017 annual shareholders' meeting for approval. The content is about the appointment of the audit firm rather than the audit report itself or the annual report. The document length is short (623 characters), and it is an announcement rather than a full audit report or annual report. Therefore, it fits best under Audit Report / Information (AR) as it relates to audit information but is not the full annual report. FY 2018
2018-04-25 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.